Sanofi (SNYNF) SEC Filings — 2024
35 SEC filings for Sanofi (SNYNF) in 2024.
Filings
- Sanofi Board Addition & Phase 3 Launch — 6-K · Dec 23, 2024
- Sanofi's tolebrutinib gets FDA Breakthrough Therapy nod for MS — 6-K · Dec 20, 2024
- Sanofi Files 6-K with December Press Releases — 6-K · Dec 13, 2024
- Sanofi's Sarclisa gets EU nod for multiple myeloma — 6-K · Nov 18, 2024
- Sanofi's Dupixent Gets EU Approval for Young EoE Patients — 6-K · Nov 7, 2024
- Sanofi SC 13G/A Filing — SC 13G/A · Nov 7, 2024
- Sanofi to Present Dupixent CSU Phase 3 Data at ACAAI — 6-K · Oct 31, 2024
- Sanofi Files 6-K Report — 6-K · Oct 25, 2024
- Sanofi partners with Orano for radioligand medicine development — 6-K · Oct 21, 2024
- Sanofi's Beyfortus Data Show Real-World RSV Effectiveness — 6-K · Oct 11, 2024
- Sanofi's Dupixent Approved in China for COPD — 6-K · Oct 2, 2024
- Sanofi's Tolebrutinib Shows Promise in MS Trial — 6-K · Sep 24, 2024
- Sanofi's Dupixent Shows Promise in Bullous Pemphigoid — 6-K · Sep 13, 2024
- Sanofi's Tolebrutinib Succeeds in Phase 3 MS Study — 6-K · Sep 3, 2024
- Sanofi's Sarclisa Shows Improved Survival in Multiple Myeloma — 6-K · Aug 13, 2024
- Sanofi Files 6-K with H1 2024 Financial Data — 6-K · Jul 25, 2024
- Sanofi's Dupixent Gets EU Approval for COPD — 6-K · Jul 23, 2024
- Sanofi Files 6-K with June Press Releases — 6-K · Jul 2, 2024
- Sanofi's Dupixent Gets FDA Priority Review for COPD — 6-K · Jun 11, 2024
- Sanofi SC 13G Filing — SC 13G · May 31, 2024
- Sanofi prices $3.5B Green Senior Notes — 6-K · May 30, 2024
- Sanofi partners with Novavax on COVID-19 vaccine — 6-K · May 28, 2024
- Sanofi 6-K: Frexalimab MS Data & More — 6-K · May 2, 2024
- Sanofi Files 6-K Report for April 2024 — 6-K · Apr 25, 2024
- Sanofi's amlitelimab shows promise in atopic dermatitis Phase 2b trial — 6-K · Mar 20, 2024
- Sanofi's Frexalimab Shows High Efficacy in MS Phase 2 Data — 6-K · Feb 27, 2024
- Sanofi Files 20-F Report for Fiscal Year Ended December 31, 2023 — 20-F · Feb 23, 2024
- Sanofi Launches Global Employee Support Program — 6-K · Feb 15, 2024
- Sanofi SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- Sanofi SC 13G/A Filing — SC 13G/A · Feb 13, 2024
- BlackRock Amends Sanofi Stake, Maintains Significant Holding — SC 13G/A · Feb 6, 2024
- Sanofi's Dupixent FDA Approved for EoE in Young Children; New CFO Appointed — 6-K · Feb 2, 2024
- Sanofi Reports Solid Sales & EPS Growth, Driven by New Products — 6-K · Feb 1, 2024
- Sanofi to Acquire Inhibrx for Rare Disease Asset, Boosting Pipeline — 6-K · Jan 23, 2024
- Sanofi Appoints Brian Foard Head of Specialty Care GBU, Executive Committee Member — 6-K · Jan 17, 2024